Literature DB >> 24914139

Current issues in chronic graft-versus-host disease.

Gérard Socié1, Jerome Ritz2.   

Abstract

Chronic graft-versus-host disease (GVHD) is a frequent and potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation. Increased transplantation of older patients and the more frequent use of unrelated donors has led to increased numbers of patients with this painful complication. Recent advances have been made in understanding the pathophysiology of chronic GVHD and in establishing precise criteria for diagnosis and classification of disease manifestations. These advances will hopefully pave the way for improving both the prophylaxis and treatment of chronic GVHD.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2014        PMID: 24914139      PMCID: PMC4102710          DOI: 10.1182/blood-2014-01-514752

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  96 in total

1.  Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.

Authors:  David A Jacobsohn; Brenda F Kurland; Joseph Pidala; Yoshihiro Inamoto; Xiaoyu Chai; Jeanne M Palmer; Sally Arai; Mukta Arora; Madan Jagasia; Corey Cutler; Daniel Weisdorf; Paul J Martin; Steven Z Pavletic; Georgia Vogelsang; Stephanie J Lee; Mary E D Flowers
Journal:  Blood       Date:  2012-07-06       Impact factor: 22.113

2.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Whitney S Washel; Nazmim S Bhuiya; Corey S Cutler; Edwin P Alyea; Vincent T Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

3.  Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells.

Authors:  Raewyn Broady; Jie Yu; Vickie Chow; Adisak Tantiworawit; Christine Kang; Kyra Berg; Magdalena Martinka; Mehran Ghoreishi; Jan Dutz; Megan K Levings
Journal:  Blood       Date:  2010-09-23       Impact factor: 22.113

4.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.

Authors:  Joseph Pidala; Brenda Kurland; Xiaoyu Chai; Navneet Majhail; Daniel J Weisdorf; Steven Pavletic; Corey Cutler; David Jacobsohn; Jeanne Palmer; Sally Arai; Madan Jagasia; Stephanie J Lee
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

5.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

6.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease.

Authors:  Yoshihiro Inamoto; Barry E Storer; Stephanie J Lee; Paul A Carpenter; Brenda M Sandmaier; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group.

Authors:  Hisaki Fujii; Geoff Cuvelier; Kevin She; Soudabeh Aslanian; Hiromi Shimizu; Amina Kariminia; Mark Krailo; Zhengjia Chen; Rob McMaster; Axel Bergman; Frederick Goldman; Stephen A Grupp; Donna A Wall; Andrew L Gilman; Kirk R Schultz
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

8.  Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

Authors:  Sibel Koc; Wendy Leisenring; Mary E D Flowers; Claudio Anasetti; H Joachim Deeg; Richard A Nash; Jean E Sanders; Robert P Witherspoon; Rainer Storb; Frederick R Appelbaum; Paul J Martin
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

9.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.

Authors:  Paul J Martin; George W Counts; Frederick R Appelbaum; Stephanie J Lee; Jean E Sanders; H Joachim Deeg; Mary E D Flowers; Karen L Syrjala; John A Hansen; Rainer F Storb; Barry E Storer
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

10.  Feasibility of NIH consensus criteria for chronic graft-versus-host disease.

Authors:  B-S Cho; C-K Min; K-S Eom; Y-J Kim; H-J Kim; S Lee; S-G Cho; D-W Kim; J-W Lee; W-S Min; C-C Kim
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

View more
  150 in total

1.  Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.

Authors:  Zoya Kuzmina; Verena Gounden; Lauren Curtis; Daniele Avila; Tiffani Taylor Rnp; Judy Baruffaldi; Edward W Cowen; Haley B Naik; Sarfaraz A Hasni; Jacqueline W Mays; Sandra Mitchell; Kristin Baird; Seth M Steinberg; Steven Z Pavletic
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

Review 2.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

3.  Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes.

Authors:  Hideki Nakasone; Bita Sahaf; Lu Tian; Tao Wang; Michael D Haagenson; Kelsi Schoenrock; Spenser Perloff; Christine E Ryan; Fang Wu; Stephen R Spellman; Stephanie J Lee; Jerome Ritz; David B Miklos
Journal:  Haematologica       Date:  2015-10-22       Impact factor: 9.941

4.  Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.

Authors:  Z DeFilipp; M Purcell; W A C Harris; D J Chandra; C Gleason; J Wrammert; S Sarantopoulos; E K Waller
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

5.  Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects.

Authors:  Grégory Ehx; Gilles Fransolet; Laurence de Leval; Stéphanie D'Hondt; Sophie Lucas; Muriel Hannon; Loïc Delens; Sophie Dubois; Pierre Drion; Yves Beguin; Stéphanie Humblet-Baron; Frédéric Baron
Journal:  Oncoimmunology       Date:  2017-04-12       Impact factor: 8.110

6.  Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.

Authors:  Roger Belizaire; Haesook T Kim; Samuel J Poryanda; Nikola V Mirkovic; Evelyn Hipolito; William J Savage; Carol G Reynolds; Marie J Fields; Jennifer Whangbo; Tomohiro Kubo; Sarah Nikiforow; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Bruce R Blazar; Joseph H Antin; Jerome Ritz; Robert J Soiffer; John Koreth
Journal:  Blood Adv       Date:  2019-04-09

7.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Authors:  Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño
Journal:  Blood Adv       Date:  2018-07-24

8.  Ceramide synthesis regulates T cell activity and GVHD development.

Authors:  M Hanief Sofi; Jessica Heinrichs; Mohammed Dany; Hung Nguyen; Min Dai; David Bastian; Steven Schutt; Yongxia Wu; Anusara Daenthanasanmak; Salih Gencer; Aleksandra Zivkovic; Zdzislaw Szulc; Holger Stark; Chen Liu; Ying-Jun Chang; Besim Ogretmen; Xue-Zhong Yu
Journal:  JCI Insight       Date:  2017-05-18

Review 9.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

Review 10.  Mesenchymal stem cells in the treatment of inflammatory and autoimmune diseases in experimental animal models.

Authors:  Matthew W Klinker; Cheng-Hong Wei
Journal:  World J Stem Cells       Date:  2015-04-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.